Company intelligence / Profile preview
Ascenta Therapeutics
Malvern, Pennsylvania, United Statesdebiopharm.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Ascenta Therapeutics developed orally active small molecule drugs targeting apoptosis pathways in cancer cells. Lead compounds included AT‑101 (pan-Bcl‑2 inhibitor) in Phase IIb clinical trials and AT‑406 (IAP inhibitor) in early clinical development. The company also advanced an HDM2/p53 program through a major partnership with Sanofi-Aventis. In 2010, Ascenta was acquired by Sanofi.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Sanofi-AventisAscentage Pharma Group
Beyond the preview
Go deeper on Ascenta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ascenta Therapeutics.